Gene expression before haart initiation predicts hiv-infected individuals at risk of poor cd4+ t-cell recovery

AIDS

Volumn 24, Issue 2, 2010, Pages 217-222

  Woelk, Christopher H ^a,b   Beliakova Bethell, Nadejda ^c   Goicoechea, Miguel ^a   Zhao, Yingdong ^d   Du, Pinyi ^a   Rought, Steffney E ^a   Lozach, Jean ^e   Pérez Santiago, Josué ^a   Richman, Douglas D ^a,b,c   Smith, Davey M ^a,b   Little, Susan J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ILLUMINA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; TRANSCRIPTOME;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 74249102034     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328334f1f0     Document Type: Article

References (27)

1. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G. The absence of CD4R T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-337.
2. Schechter M, Tuboi SH. Discordant immunological and viro-logical responses to antiretroviral therapy. J Antimicrob Che-mother 2006; 58:506-510.
3. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, et al. Determinants of CD4R T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194:29-37.
4. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatch-kine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-1335.
5. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. J Infect Dis 2006; 194:1098-1107.
6. Motomura K, Toyoda N, Oishi K, Sato H, Nagai S, Hashimoto S, et al. Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals. Int Immunopharmacol 2004; 4:1829-1836.
7. Ockenhouse CF, Bernstein WB, Wang Z, Vahey MT. Functional genomic relationships in HIV-1 disease revealed by gene-expression profiling of primary human peripheral blood mono-nuclear cells. J Infect Dis 2005; 191:2064-2074.
8. Vahey MT, Wang Z, Su Z, Nau ME, Krambrink A, Skiest DJ, Margolis DM. CD4R T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Res Hum Retroviruses 2008; 24:1047-1066.
9. Tateno M, Honda M, Kawamura T, Honda H, Kaneko S. Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy. J Infect Dis 2007; 195:255-267.
10. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003; 63:6069-6075.
11. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 2005; 11:1181-1189.
12. DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, et al. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003; 3:3.
13. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N, et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 2005; 102:15533-15538.
14. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, Shalev AY. Peripheral blood mononuclear cell gene expression profiles identify emergent posttraumatic stress disorder among trauma survivors. Mol Psychiatry 2005; 10:500-513; 425. (Pubitemid 40646438)
15. Woelk CH, Burczynski ME. The clinical relevance of gene expression profiles in peripheral blood mononuclear cells. In: Columbus F, editor. Oligonucleotide array sequence analysis. Hauppage, NY: NOVA Publishing; 2008. pp. 38-50.
16. Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 2006; 7:187-202.
17. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99:6567-6572.
18. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.
19. Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194:734-739.
20. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
21. Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing illumina microarray. Bioinformatics 2008; 24:1547-1548.
22. BolstadBM, Collin F, BrettschneiderJ, Simpson K, CopeL, Irizarry R, Speed TP. Quality assessment of affymetrix GeneChip data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dutoit S, editors. Bioinformatics and computational biology solutions using R and bioconductor Heidelberg: Springer; 2005. pp. 33-47.
23. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-127.
24. Simon R, Lam A, Li M, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007; 2:11-17.
25. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat 2004; 32:407-499.
26. Simon R, the BRB-Array Tools Development Team, the EMMES Corporation. BRB-Array Tools Version 3.8 User's Manual; 2009. http://linus.nci.nih.gov/~brb/ download-full-v3-8.html.
27. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23:7332-7341.